Antiangiogenic Activity of Genistein in Pancreatic Carcinoma Cells Is Mediated by the Inhibition of Hypoxia-Inducible Factor-1 and the Down-Regulation of VEGF Gene Expression

Cancer

Volumn 100, Issue 1, 2004, Pages 201-210

  Büchler, Peter ^a,b   Reber, Howard A ^a   Büchler, Markus W ^b   Friess, Helmut ^b   Lavey, Robert S ^c   Hines, Oscar J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Genistein; Hypoxia inducible factor 1; Pancreatic carcinoma; Pancreatic carcinoma model; Vascular endothelial growth factor

Indexed keywords

GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1; ISOFLAVONOID; MESSENGER RNA; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; DNA BINDING; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIC CELL; INCUBATOR; NORTHERN BLOTTING; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CARCINOMA; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HELIX-LOOP-HELIX MOTIFS; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346217046     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11873     Document Type: Article

References (54)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117:1464-1484.
2. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin. 1998;48: 31-48.
3. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
4. Friess H, Uhl W, Büchler MW. Surgical treatment of pancreatic cancer. Dig Surg. 1994;11:378-386.
5. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg. 1998;2:159-166.
6. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
7. Wenger C, Ellenrieder V, Alber B, et al. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene. 1999;18:1073-1080.
8. Di Mola FF, Friess H, Riesle E, et al. Connective tissue growth factor is involved in pancreatic repair and tissue remodeling in human and rat acute necrotizing pancreatitis. Ann Surg. 2002;235:60-67.
9. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48:919-922.
10. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003;26:56-64.
11. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90:4304-4308.
12. Dvorak HF, Detmar M, Claffey KP, Nagy JA, Van De Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995;107:233-235.
13. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991;174:1275-1278.
14. El Awad B, Kreft B, Wolber EM, et al. Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 2000;58:43-50.
15. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
16. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 2000;60:4010-4015.
17. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.
18. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993;90:2690-2694.
19. Fotsis T, Pepper MS, Aktas E, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997;57:2916-2921.
20. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 1998;58:4851-4857.
21. Buchler P, Gukovskaya AS, Mouria M, et al. Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with Genistein, a naturally occurring isoflavonoid. Pancreas. 2003;26:264-273.
22. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5595.
23. Chang YC, Nair MG. Metabolites of daidzein and genistein and their biological activities. J Nat Prod. 1995;58:1901-1905.
24. Buchler P, Reber HA, Buchler MC, et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg. 2001;5:139-146.
25. Hotz HG, Hines OJ, Foitzik T, Reber HA. Animal models of exocrine pancreatic cancer. Int J Colorectal Dis. 2000;15:136-143.
26. Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer. 2002;98:761-769.
27. Friess H, Lu Z, Graber HU, et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 1998;43:414-421.
28. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
29. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol. 1996:167-190.
30. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;32A:2474-2484.
31. 2 tension measurements. Cancer Res. 1991;51:3316-3322.
32. Price MJ, Li LT, Tward JD, Bublik I, McBride WH, Lavey RS. Effect of nicotinamide and pentoxifylline on normal tissue and FSA tumor oxygenation. Acta Oncol. 1995;34:391-395.
33. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375:577-581.
34. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604-4613.
35. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89:5645-5649.
36. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 2003;26:E89-E98.
37. Ihse I, Permert J, Andersson R, et al. [Guidelines for management of patients with pancreatic cancer]. Lakartidningen. 2002;99:1676-1680, 1683-1685.
38. 2 homeostasis. Curr Opin Genet Dev. 1998;5:588-594.
39. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997;272:19253-19260.
40. Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing. Cell. 1997;89:9-12.
41. Brown JM, Giaccia AJ. The unique physiology of solid tumors. Opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-1416.
42. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88-91.
43. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59:520-529.
44. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
45. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 2000;14:34-44.
46. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
47. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628-1635.
48. Uckun FM, Evans WE, Forsyth CJ, et al. Biotherapy of B-cell precursor leukemia by targeting Genistein to CD-19-associated tyrosine kinases. Science. 1995;267:886-891.
49. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr. 1995;125:790S-797S.
50. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.
51. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature. 1997;387: 561.
52. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A. 1996;93:10589-10594.
53. Shih SC, Claffey KP. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem. 1999;274:1359-1365.
54. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 1996;271:2746-2753.